Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
Avtorji:ID Mencinger, Marina (Avtor)
ID Mangaroski, Dushan (Avtor)
ID Bokal, Urška (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647786/pdf/raon-55-491.pdf
 
.pdf PDF - Predstavitvena datoteka, prenos (718,26 KB)
MD5: 1FC8E59EA70A94614F56BEB76B262E3E
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.Patients and methods. 62 patients with mUC, treated at the Institute of Oncology Ljubljana between May 8th 2018 and Dec 31st 2019, were included. Response rates and immune-related adverse events (irAE) were collected. Progression-free survival and overall survival times were assessed using the Kaplan-Meier method. The Cox propor-tional hazards model was applied to identify the factors affecting survival. Results. Of 62 patients, five (8.1%) have not yet been evaluated and 20 (32%) died prior to the first radiographic evaluation. We observed clinical benefit in 19 (33%), objective response in 12 (21%), and complete response in five (9%) patients. Median overall survival for the whole population was 6.8 (95% CI, 2.6–11.0), for platinum-naïve 8.7 (95% CI: 0.8–16.5), and for the platinum-treated group 6.8 (95% CI, 3.7–10) months. At the 5.8 (0.3–23.1) month median follow-up, the median duration of the response was not reached. IrAE occurred in 20 (32%) patients and seven (11%) of them discontinued the treatment. Multivariate analysis in platinum-treated patients showed that a treatment-free interval of more than six months was prognostic for overall survival (OS). Conclusions. Responses to atezolizumab led to long disease remission in a subset of our patients. The median OS in our real-world population was compromised by a large percentage of patients with poor ECOG performance status (PS). A treatment-free interval from chemotherapy was associated with the longer survival of platinum-treated pa-tients with mUC receiving further atezolizumab.
Ključne besede:PD-L1 inhibitor, urothelial cancer, bladder, atezolizumab
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.01.2021
Založnik:Association of Radiology and Oncology
Leto izida:2021
Št. strani:str. 491-498, XII
Številčenje:Vol. 55, no. 4
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19673 Novo okno
UDK:616-006
ISSN pri članku:1318-2099
DOI:10.2478/raon-2021-0021 Novo okno
COBISS.SI-ID:92836867 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:23.07.2024
Število ogledov:496
Število prenosov:257
Metapodatki:XML DC-XML DC-RDF
:
MENCINGER, Marina, MANGAROSKI, Dushan in BOKAL, Urška, 2021, Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice. Radiology and oncology [na spletu]. 2021. Vol. 55, no. 4, p. 491–498, xii. [Dostopano 12 april 2025]. DOI 10.2478/raon-2021-0021. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=19673
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:zaviralec PD-L1, rak sečnih organov, mehur, kemoterapija


Nazaj